Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On January 19, 2022, the Board of Directors (the "Board") of Akebia
Therapeutics, Inc. (the "Company") approved an amendment and restatement of the
Company's Cash Incentive Plan (the "Amended Plan"). The Amended Plan no longer
includes provisions that were specific to compliance with the performance-based
compensation exception previously available under Section 162(m) of the Internal
Revenue Code of 1986, as amended, but that has been repealed, and includes other
procedural, conforming and clarifying changes.
The foregoing description of the Amended Plan does not purport to be complete,
and is qualified in its entirety by reference to the Amended Plan, a copy of
which the Company expects to file with its Annual Report on Form 10-K for the
year ended December 31, 2021.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses